The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia

The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3‐mutated (FLT3 (mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML). The impact of FLT3 mutation clearance and the achievement of composite complete remission (CRc) and complete remission/complete remission with par...

Descripción completa

Detalles Bibliográficos
Autores principales: Altman, Jessica K., Perl, Alexander E., Hill, Jason E., Rosales, Matt, Bahceci, Erkut, Levis, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897940/
https://www.ncbi.nlm.nih.gov/pubmed/33340276
http://dx.doi.org/10.1002/cam4.3652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897940/
https://www.ncbi.nlm.nih.gov/pubmed/33340276
http://dx.doi.org/10.1002/cam4.3652

Ejemplares similares